Physiologically based pharmacokinetic modeling at the extremes of age

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 2, 2013, Pages 148-

  Johnston, C ^a,b   Kirkpatrick, C M ^c   McLachlan, A J ^a,d   Hilmer, S N ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ABSORPTION; DRUG CONTROL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESEARCH; EXPERIMENTAL MODEL; GROUPS BY AGE; HUMAN; LETTER; NONHUMAN; PHARMACOKINETIC MODEL; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

DRUG APPROVAL; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PROCESSES;

EID: 84872681897     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.176     Document Type: Letter

References (5)

1. Barrett, J.S., Della Casa Alberighi, O., Läer, S. & Meibohm B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin. Pharmacol. Ther. 92, 40-49 (2012).
2. Hilmer, S.N., Gnjidic, D. & Abernethy, D.R. Pharmacoepidemiology in the postmarketing assessment of the safety and efcacy of drugs in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 67, 181-188 (2012).
3. McLachlan, A.J., Hilmer, S.N. & Le Couteur, D.G. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin. Pharmacol. Ther. 85, 431-433 (2009).
4. Schwartz, J.B. & Verotta, D. Population analyses of atorvastatin clearance in patients living in the community and in nursing homes. Clin. Pharmacol. Ther. 86, 497-502 (2009).
5. Expert Working Group (ICH) Guideline for Industry. Studies in Support of Special Populations: Geriatrics http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM129519.pdf (1994).